These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17897483)

  • 1. Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells.
    Newman-Tancredi A; Heusler P; Martel JC; Ormière AM; Leduc N; Cussac D
    Int J Neuropsychopharmacol; 2008 May; 11(3):293-307. PubMed ID: 17897483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
    Heusler P; Newman-Tancredi A; Castro-Fernandez A; Cussac D
    Neuropharmacology; 2007 Mar; 52(4):1106-13. PubMed ID: 17239906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of dopaminergic compounds at hD2short, hD4.2 and hD4.7 receptors in agonist-stimulated [35S]GTPgammaS binding assays.
    Gilliland SL; Alper RH
    Naunyn Schmiedebergs Arch Pharmacol; 2000 May; 361(5):498-504. PubMed ID: 10832603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation.
    Bruins Slot LA; Palmier C; Tardif S; Cussac D
    Neuropharmacology; 2007 Aug; 53(2):232-41. PubMed ID: 17588617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [35S]GTPgammaS binding at the human dopamine D4 receptor variants hD4.2, hD4.4 and hD4.7 following stimulation by dopamine, epinephrine and norepinephrine.
    Czermak C; Lehofer M; Liebmann PM; Traynor J
    Eur J Pharmacol; 2006 Feb; 531(1-3):20-4. PubMed ID: 16423344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clozapine metabolite N-desmethylclozapine displays variable activity in diverse functional assays at human dopamine D₂ and serotonin 5-HT₁A receptors.
    Heusler P; Bruins Slot L; Tourette A; Tardif S; Cussac D
    Eur J Pharmacol; 2011 Nov; 669(1-3):51-8. PubMed ID: 21835172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
    Newman-Tancredi A; Gavaudan S; Conte C; Chaput C; Touzard M; Verrièle L; Audinot V; Millan MJ
    Eur J Pharmacol; 1998 Aug; 355(2-3):245-56. PubMed ID: 9760039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.
    Newman-Tancredi A; Assié MB; Leduc N; Ormière AM; Danty N; Cosi C
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):341-56. PubMed ID: 15707540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors.
    Newman-Tancredi A; Cussac D; Audinot V; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):447-53. PubMed ID: 10431754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
    Bruins Slot LA; De Vries L; Newman-Tancredi A; Cussac D
    Eur J Pharmacol; 2006 Mar; 534(1-3):63-70. PubMed ID: 16497294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes.
    Odagaki Y; Toyoshima R
    Clin Exp Pharmacol Physiol; 2007; 34(5-6):462-6. PubMed ID: 17439416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
    Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
    Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional activation by central monoamines of human dopamine D(4) receptor polymorphic variants coupled to GIRK channels in Xenopus oocytes.
    Wedemeyer C; Goutman JD; Avale ME; Franchini LF; Rubinstein M; Calvo DJ
    Eur J Pharmacol; 2007 May; 562(3):165-73. PubMed ID: 17350612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
    Oz M; Zhang L; Rotondo A; Sun H; Morales M
    Synapse; 2003 Dec; 50(4):303-13. PubMed ID: 14556235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
    J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.